Corcept Therapeutics is rated hold due to high binary risk from an imminent Teva lawsuit decision impacting Korlym sales. Exceptional Phase 3 data for relacorilant in platinum-resistant ovarian cancer ...
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' (CORT.O), opens new tab drug for the treatment of a rare hormonal disorder, the company said on ...
This special distribution is in addition to the Fund's previously announced December distribution of $0.45 per share. This special distribution is being paid to allow the Fund to meet its 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback